Nature Biotechnology, Published online: 19 August 2026; doi:10.1038/s41587-026-03238-6 A prospective, blinded competition is conducted for artificial-intelligence-generated and optimized antibody discovery.
ORIGINAL PAPER
A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability
WHAT WE KNOW
Nature Biotechnology, Published online: 19 August 2026; doi:10.1038/s41587-026-03238-6 A prospective, blinded competition is conducted for artificial-intelligence-generated and optimized antibody discovery.
WATCH NEXT
Review the primary source, validate the main result, and establish whether any listed-company transmission is direct.
EVIDENCE
What the evidence supports so far
Research signals
AI-drug-discovery
protein-design
What remains unverified
The full methodology, effect size, and limitations still require analyst review.
Company impact remains unverified until a direct economic transmission is established.